Yahoo
Stockholm - Delayed Quote SEK

Isofol Medical AB (publ) (ISOFOL.ST)

1.1980 +0.0100 (+0.84%)
At close: October 30 at 12:59:33 PM GMT+1
Chart Range Bar
Loading chart for ISOFOL.ST
  • Previous Close 1.1880
  • Open 1.1900
  • Bid 1.1860 x --
  • Ask 1.1980 x --
  • Day's Range 1.1460 - 1.2300
  • 52 Week Range 0.5515 - 1.2500
  • Volume 1,075,721
  • Avg. Volume 697,165
  • Market Cap (intraday) 383.949M
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1.70

Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.

isofolmedical.com

7

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

ISOFOL.ST
64.33%
OMX Stockholm 30 Index (^OMX)
13.47%

1-Year Return

ISOFOL.ST
74.64%
OMX Stockholm 30 Index (^OMX)
17.56%

3-Year Return

ISOFOL.ST
54.78%
OMX Stockholm 30 Index (^OMX)
59.03%

5-Year Return

ISOFOL.ST
85.97%
OMX Stockholm 30 Index (^OMX)
42.80%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -12.78M
Profit Margin 0.00%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

1.70
1.70 Average
1.1980 Current
1.70 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -39.03%

  • Return on Equity (ttm)

    -78.31%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -56.63M

  • Diluted EPS (ttm)

    -0.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    114.83M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -32.84M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: